121 related articles for article (PubMed ID: 9345404)
1. Treatment of relapsing-remitting multiple sclerosis with natural interferon beta: a multicenter, randomized clinical trial.
Fernández O; Antiquëdad A; Arbizu T; Capdevíla A; de Castro P; Correa de Sa JC; García-Merino JA; Izquierdo G; Magalhaes A; Montalbán X
Mult Scler; 1995; 1 Suppl 1():S67-9. PubMed ID: 9345404
[TBL] [Abstract][Full Text] [Related]
2. [Natural interferon-beta in the treatment of relapsing-remitting multiple sclerosis: a multicenter, randomized, MRI-based, phase II clinical trial].
Fernández O; Antigüedad A; Arbizu T; Burgués S; Capdevila A; de Castro P; Correa de Sá JC; García-Merino JA; Izquierdo G; Magalhaes A; Montalbán X; Zarranz JJ
Rev Neurol; 1999 Dec 16-31; 29(12):1093-9. PubMed ID: 10652728
[TBL] [Abstract][Full Text] [Related]
3. Human recombinant interferon beta in the treatment of relapsing-remitting multiple sclerosis: preliminary observations.
Fieschi C; Pozzilli C; Bastianello S; Koudriavtseva T; Gasperini C; Bozzao A; Galgani S; Paolillo A; Millefiorini E; Buttinelli C
Mult Scler; 1995; 1 Suppl 1():S28-31. PubMed ID: 9345395
[TBL] [Abstract][Full Text] [Related]
4. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
Schwid SR; Panitch HS
Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
[TBL] [Abstract][Full Text] [Related]
5. Recombinant human interferon beta in the treatment of relapsing-remitting and secondary progressive multiple sclerosis.
Sandberg-Wollheim M; Hommes OR; Hughes RA; Paty DW; Abdul-Ahad AK
Mult Scler; 1995; 1 Suppl 1():S48-50. PubMed ID: 9345399
[TBL] [Abstract][Full Text] [Related]
6. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
[TBL] [Abstract][Full Text] [Related]
7. Effect of dose and frequency of interferon beta-1a administration on clinical and magnetic resonance imaging parameters in relapsing-remitting multiple sclerosis.
Cocco E; Marchi P; Floris G; Mascia MG; Deriu M; Sirca A; Mamusa E; Lai M; Mura M; Mallarini G; Marrosu MG
Funct Neurol; 2006; 21(3):145-9. PubMed ID: 17049133
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study.
Cadavid D; Wolansky LJ; Skurnick J; Lincoln J; Cheriyan J; Szczepanowski K; Kamin SS; Pachner AR; Halper J; Cook SD
Neurology; 2009 Jun; 72(23):1976-83. PubMed ID: 19279320
[TBL] [Abstract][Full Text] [Related]
9. Interferon beta-1b in secondary progressive multiple sclerosis--outline of the clinical trial.
Polman CH; Dahlke F; Thompson AJ; Ghazi M; Kappos L; Miltenburger C; Pozilli C
Mult Scler; 1995; 1 Suppl 1():S51-4. PubMed ID: 9345400
[TBL] [Abstract][Full Text] [Related]
10. Early treatment of multiple sclerosis with Rebif (recombinant human interferon beta): design of the study.
Comi G; Barkhof F; Durelli L; Edan G; Fernandez O; Filippi M; Hartung HP; Hommes OR; Seeldrayers P; Soelberg-Sorensen P
Mult Scler; 1995; 1 Suppl 1():S24-7. PubMed ID: 9345394
[TBL] [Abstract][Full Text] [Related]
11. High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study.
Barbero P; Verdun E; Bergui M; Pipieri A; Clerico M; Cucci A; Ricci A; Bergamasco B; Durelli L
J Neurol Sci; 2004 Jul; 222(1-2):13-9. PubMed ID: 15240190
[TBL] [Abstract][Full Text] [Related]
12. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
Kappos L; Traboulsee A; Constantinescu C; Erälinna JP; Forrestal F; Jongen P; Pollard J; Sandberg-Wollheim M; Sindic C; Stubinski B; Uitdehaag B; Li D
Neurology; 2006 Sep; 67(6):944-53. PubMed ID: 17000959
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.
Minagar A; Alexander JS; Schwendimann RN; Kelley RE; Gonzalez-Toledo E; Jimenez JJ; Mauro L; Jy W; Smith SJ
Arch Neurol; 2008 Feb; 65(2):199-204. PubMed ID: 18071030
[TBL] [Abstract][Full Text] [Related]
14. Magnetic resonance imaging as an outcome measure in the treatment of multiple sclerosis: results of the interferon beta trial.
Koopmans RA; Paty DW
Mult Scler; 1995; 1 Suppl 1():S22-3. PubMed ID: 9345393
[No Abstract] [Full Text] [Related]
15. Interferon alpha treatment of relapsing-remitting multiple sclerosis: long-term study of the correlations between clinical and magnetic resonance imaging results and effects on the immune function.
Durelli L; Bongioanni MR; Cavallo R; Ferrero B; Ferri R; Verdun E; Bradac GB; Riva A; Geuna M; Bergamini L
Mult Scler; 1995; 1 Suppl 1():S32-7. PubMed ID: 9345396
[TBL] [Abstract][Full Text] [Related]
16. Early treatment trials with interferon beta in multiple sclerosis.
Panitch HS
Mult Scler; 1995; 1 Suppl 1():S17-21. PubMed ID: 9345392
[TBL] [Abstract][Full Text] [Related]
17. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group.
Neurology; 1995 Jul; 45(7):1277-85. PubMed ID: 7617182
[TBL] [Abstract][Full Text] [Related]
18. Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study.
Saida T; Tashiro K; Itoyama Y; Sato T; Ohashi Y; Zhao Z;
Neurology; 2005 Feb; 64(4):621-30. PubMed ID: 15728282
[TBL] [Abstract][Full Text] [Related]
19. Disease-modifying therapy in relapsing--remitting multiple sclerosis: efficacy is paramount.
Cristiano E
Int J Clin Pract Suppl; 2002 Sep; (131):3-7. PubMed ID: 12564806
[TBL] [Abstract][Full Text] [Related]
20. Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study.
Schwid SR; Thorpe J; Sharief M; Sandberg-Wollheim M; Rammohan K; Wendt J; Panitch H; Goodin D; Li D; Chang P; Francis G; ;
Arch Neurol; 2005 May; 62(5):785-92. PubMed ID: 15883267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
